Myovant's Relugolix Shows Promising Profile For Endometriosis Pain

The first Phase III trial testing relugolix combination therapy in endometriosis pain showed efficacy with minimal bone mineral density loss, an issue with AbbVie's rival drug Orilissa. An US NDA was also filed in prostate cancer.

A chess king last stand as a true winner.Money game concept. Copy space. — Myovant's Orilissa appears to have a competitive profile • Source: Shutterstock

Myovant Sciences Ltd.'s relugolix appears well positioned to compete against AbbVie Inc.'s Orilissa (elagolix), which it will trail to the market, for endometriosis pain. Relugolix demonstrated significant reductions in endometriosis pain in the first of two Phase III studies to read out, and with minimal bone mineral density (BMD) loss, a safety issue associated with Orilissa.

Myovant announced positive data from the first Phase III trial in endometriosis pain on 22 April, one day after the company said it filed a new drug application with the US Food and Drug Administration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.